The French biotech Valneva will collaborate with Pfizer to develop and commercialize Valneva’s phase II-stage Lyme disease vaccine candidate. The deal they signed is expected to help compensate for the impact of the Covid-19 pandemic on Valneva’s financial outlook for 2020.
The latest alliance will pool Valneva’s vaccine R&D expertise with Pfizer’s vast drug development resources. If approved, the vaccine could become the first on the market for the tick-borne Lyme disease since SmithKline Beecham’s (now GlaxoSmithKline) vaccine LYMErix was withdrawn in 2002.
Click here to read full article https://www.labiotech.eu/medical/pfizer-valneva-lyme-disease/